Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$102.80 USD

102.80
384,755

-2.21 (-2.11%)

Updated Sep 20, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Ligand Pharmaceuticals Incorporated [LGND]

Reports for Purchase

Showing records 481 - 500 ( 720 total )

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 481

10/27/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 482

10/26/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 483

10/23/2015

Company Report

Pages: 4

Appears Evomela CRL Should be Non- Event; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 484

10/23/2015

Company Report

Pages: 6

Evomela CRL; Buffered Downside for Ligand; Target Tweaked

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 485

10/19/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 486

10/19/2015

Company Report

Pages: 14

Prepping for Sparsentan; Time to Remind on Investment Case

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 487

10/06/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 488

09/30/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 489

09/30/2015

Company Report

Pages: 8

Expecting Strong 3Q15; Support by Broad Opportunities; Target to $140

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 490

09/21/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 491

09/21/2015

Daily Note

Pages: 4

Looking for Another Kyprolis Label Expansion; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 492

09/09/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 493

09/02/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 494

09/02/2015

Company Report

Pages: 12

Promacta, Evomela and Good Looking Scripts; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 495

08/25/2015

Industry Report

Pages: 6

Biotech Names for the Turn and the Long Haul

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 496

08/24/2015

Company Report

Pages: 4

Additional Promacta Label Expansion Highlights Growth Path

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 497

08/10/2015

Company Report

Pages: 6

2Q15 Results; Strong Commercial and Licensing Momentum; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 498

08/10/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 499

08/10/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 500

07/31/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party
// eof